Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cogent Biosciences (COGT) Cash from Financing Activities (2017 - 2021)

Cogent Biosciences (COGT) has 4 years of Cash from Financing Activities data on record, last reported at $38.0 million in Q4 2021.

  • For Q4 2021, Cash from Financing Activities fell 68.88% year-over-year to $38.0 million; the TTM value through Dec 2021 reached $38.0 million, down 83.64%, while the annual FY2025 figure was $878.2 million, 309.53% up from the prior year.
  • Cash from Financing Activities reached $38.0 million in Q4 2021 per COGT's latest filing, up from $55000.0 in the prior quarter.
  • Across five years, Cash from Financing Activities topped out at $122.1 million in Q4 2020 and bottomed at -$535000.0 in Q1 2018.
  • Average Cash from Financing Activities over 4 years is $26.2 million, with a median of $97000.0 recorded in 2019.
  • Peak YoY movement for Cash from Financing Activities: skyrocketed 563.64% in 2020, then crashed 216.44% in 2021.
  • A 4-year view of Cash from Financing Activities shows it stood at $395000.0 in 2018, then crashed by 75.44% to $97000.0 in 2019, then surged by 125813.4% to $122.1 million in 2020, then tumbled by 68.88% to $38.0 million in 2021.
  • Per Business Quant database, its latest 3 readings for Cash from Financing Activities were $38.0 million in Q4 2021, $55000.0 in Q3 2021, and -$85000.0 in Q1 2021.